Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

104.24 +0.28 (+0.27%)
Streaming Delayed Price Updated: 2:19 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
70 71 Next >
Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant
 
Via Benzinga
7 Biotech Stocks With Key Catalysts Coming in July
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
From Pfizer Inc.
Via Business Wire
BioNTech Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 14 strange trades. 
Via Benzinga
BioNTech Whale Trades For June 10
A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 10 strange trades. 
Via Benzinga
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BioNTech Gets EMA's Priority Medicines Status For Testicular Cancer Drug
BioNTech (NASDAQ: BNTX) received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its product candidate BNT211 in the third- or later-line treatment of testicular... 
Via Benzinga
7 Long-Term Stocks to Buy in a Bear Market
These long-term stocks to buy are from defensive sectors, because now is the time to play defense in your stock investing. 
Via InvestorPlace
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months
 
Via Benzinga
Pfizer, Moderna Snag FDA OK For Covid Shots In Children At 6 Months Old
The decision expands Covid shots out to the last group to become eligible. 
Via Investor's Business Daily
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Bavarian Nordic Launches COVID-19 Booster Study To Compare Against Pfizer/BioNTech Shot
 
Via Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Committee Backs Pfizer, Moderna COVID-19 Vaccines For Toddlers, Youngest Children
The FDA's Vaccines and Related Biological Products Advisory Committee voted i 
Via Benzinga
As Omicron Surges, FDA Mulls Pfizer, Moderna Covid Shots For Babies
Pfizer studied a three-dose regimen. Moderna looked at two doses. 
Via Investor's Business Daily
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Wednesday, June 15
Reuters Warner Bros Discovery To Undergo Major Global Ad Sales Team Restructuring 
Via Benzinga
FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report
Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine received unanimous backing from the FDA's committee of independent immunization experts for children ages 6 through 17. 
Via Benzinga
EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters
 
Via Benzinga
Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters
 
Via Benzinga
IBD/TIPP Poll: There's Bad News For Novavax's Covid Vaccine
Here's why its protein-based shot could struggle in the U.S. 
Via Investor's Business Daily
Moderna's Pediatric Covid Shot Is On Deck At The FDA: Here's What To Know
The FDA's vaccine experts will later vote on whether to recommend the shot. 
Via Investor's Business Daily
FDA Backs Pediatric Covid Shots; Here's Why Pfizer, Moderna Shares Crumbled
The FDA says Covid shots for children under the age of 5 are safe and effective. 
Via Investor's Business Daily
5 Biotech Stocks To Watch During The Week Of June 13
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a... 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, June 13
CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here’s Why 
Via Benzinga
Moderna's COVID-19 Vaccine Shows Safety, Effectiveness For Children Under 17 Years
 
Via Benzinga
Pfizer/BioNTech's Three-Dose COVID-19 Vaccine Safe, Effective In Younger Kids
According to the FDA briefing document, Pfizer Inc (NYSE: PFE) -BioNTech's SE (NASDAQ: 
Via Benzinga
Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern
 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Thursday, June 9
Reuters Blackstone Closes In Crown Bid After Australia Approvals: Reuters 
Via Benzinga
US Schedules Covid-19 Vaccines For Children Below Five Years
 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.